Diligence memo · auto-generated · as of July 2, 2026
Vyripharm Enterprises, L.L.C.
Vyripharm Enterprises, L.L.C. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
Vyripharm Enterprises, L.L.C. operates in Biotechnology, based in HOUSTON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Vyripharm Enterprises, L.L.C. has raised $2.3M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $2.3M on —.
Valuation (modeled)modeled
Provath models Vyripharm Enterprises, L.L.C. at approximately $3.6M (range $1.6M–$5.7M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.08× the median modeled value of Seed Biotechnology companies (1012 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
No dated round to assess.
Comparablesmixed
Capital scale ranks ahead of 30% of Biotechnology peers (4293 compared).
Modeled value ranks above 8% of those peers.
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.